drugset / Trial / NCT04044313
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in patients with advanced hepatocellular carcinoma (HCC)
Timeline
- Start
- 2019-08-01
- Primary completion
- 2021-02-01
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |